Glyceraldehyde-3-phosphate dehydrogenase, apoptosis, and neurodegenerative diseases

Annual Review of Pharmacology and Toxicology

Volumn 45, Issue , 2005, Pages 269-290

  Chuang, De Maw ^a   Hough, Christopher ^b   Senatorov, Vladimir V ^c  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^c NATIONAL EYE INSTITUTE   (United States)

Author keywords

GAPDH; Intracellular sensor; Neurodegeneration; Nuclear accumulation; Overexpression

Indexed keywords

GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; POLYGLUTAMINE;

ALZHEIMER DISEASE; APOPTOSIS; BIOACCUMULATION; CELL NUCLEUS; DEGENERATIVE DISEASE; ENZYME LOCALIZATION; GENE OVEREXPRESSION; HUMAN; HUNTINGTON CHOREA; HYPOXIA; NEUROBIOLOGY; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; STROKE; SYSTEMATIC REVIEW;

ANIMALS; APOPTOSIS; CELL DEATH; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE (PHOSPHORYLATING); HUMANS; NEURODEGENERATIVE DISEASES; OXIDATIVE STRESS;

EID: 13844318224     PISSN: 03621642     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.pharmtox.45.120403.095902     Document Type: Review

References (128)

1. Jeffery CJ. 1999. Moonlighting proteins. Trends Biochemical Sci. 24:8-11
2. Sirover MA. 1999. New insights into an old protein: the functional diversity of mammalian glyceraldehyde-3-phosphate dehydrogenase. Biochim. Biophys. Acta 1432:159-84
3. Alderete JF, Millsap KW, Lenker MW, Benchimol M. 2001. Enzymes on microbial pathogens and Trichomonas vaginalis: molecular mimicry and functional diversity. Cell. Microbiol. 3:359-70
4. Huitorel P, Pantaloni D. 1985. Bundling of microtubules by glyceraldehyde-3-phosphate dehydrogenase and its modulation by ATP. Eur. J. Biochem. 150:265-69
5. Füchtbauer A, Jockusch BM, Leberer E, Pette D. 1986. Actin-severing activity copurifies with phosphofructokinase. Proc. Natl. Acad. Sci. USA 83:9502-6
6. Glaser PE, Gross RW. 1995. Rapid plasmenylethanolamine-selective fusion of membrane bilayers catalyzed by an isoform of glyceraldehyde-3-phosphate dehydrogenase-discrimination between glycolytic and fusogenic roles of individual isoforms. Biochemistry 34:12193-203
7. Robbins AR, Ward RD, Oliver C. 1995. A mutation in glyceraldehyde-3- phosphate dehydrogenase alters endocytosis in CHO cells. J. Cell. Biol. 130:1093-104
8. Tisdale EJ. 2001. Glyceraldehyde-3-phosphate dehydrogenase is required for vesicular transport in the early secretory pathway. J. Biol. Chem. 276:2480-86
9. Ikemoto A, Bole DG, Ueda T. 2003. Glycolysis and glutamate accumlation into synaptic vesicles-role of glyceraldehyde phosphate dehydrogenase and 3-phosphogylceratekinase. J. Biol. Chem. 278:5929-40
10. Doucet JP, Tuana BS. 1991. Identification of low-molecular-weight GTP-binding proteins and their sites of interaction in subcellular-fractions from skeletal-muscle. J. Biol. Chem. 266:17613-20
11. Morgenegg G, Winkler GC, Hübscher U, Heizmann CW, Mous J, Kuenzle CC. 1986. Glyceraldehyde-3-phosphate dehydrogenase is a nonhistone protein and a possible activator of transcription in neurons. J. Neurochem. 47:54-62
12. Singh R, Green MR. 1993. Sequence-specific binding of transfer-RNA by glyceraldehyde-3-phosphate dehydrogenase. Science 259:365-68
13. Meyer-Siegler K, Mauro DJ, Seal G, Wurzer J, de Riel JK, Sirover MA. 1991. A human nuclear uracil DNA glycosylase is the 37-kDa subunit of glyceraldehyde-3-phosphate dehydrogenase. Proc. Natl. Acad. Sci. USA 88:8460-64
14. Chuang D-M, Ishitani R. 1996. A role for GAPDH in apoptosis and neurodegeneration. Nat. Med. 2:609-10
15. Sirover MA. 1997. Role of the glycolytic protein, glyceraldehyde-3- phosphate dehydrogenase, in normal cell function and in cell pathology. J. Cell. Biochem. 66:133-40
16. Berry MD, Boulton AA. 2000. Glyceraldehyde-3-phosphate dehydrogenase and apoptosis. J. Neurosci. Res. 60:150-54
17. Berry MD, Boulton AA. 2002. Aliphatic propargylamines as symptomatic and neuroprotective treatments for neurodegenerative diseases. Neurotoxicol. Teratol. 24:667-73
18. Tatton W, Chalmers-Redman R, Tatton N. 2003. Neuroprotection by deprenyl and other propargylamines; glyceraldhyde-3-phosphate dehydrogenase rather than monoamine oxidase B. J. Neural Transm. 110:509-15
19. Ishitani R, Tajima H, Takata H, Tsuchiya K, Kuwae T, et al. 2003. Proapoptotic protein glyceraldehydes-3-phosphate dehydrogenase; a possible site of action of antiapoptotic drugs. Prog. Neuropsychopharmacol. Biol. Psychiatry 27:291-301
20. Waldmeier PC, Tatton WG. 2004. Interrupting apoptosis in neurodegenerative disease: potential for effective therapy? Drug Discov. Today 9:210-18
21. Margolis RL, Chuang D-M, Post RM. 1994. Programmed cell death: implications for neuropsychiatric disorders. Biol. Psychiatry 35:946-56
22. Horvitz HR. 1999. Genetic control of programmed cell death in the nematode Caenorhabditis elegans. Canc. Res. 59(Suppl. S):1701S-6S
23. Hickey MA, Chesselet MF. 2003. Apoptosis in Huntington's disease. Progr. Neuro-Psychopharm. Biol. Psychiatry 27:255-65
24. Reynolds IJ. 1999. Mitochondrial membrane potential and the permeability transition in excitotoxicity. Ann. NY Acad. Sci. 893:33-41
25. Hengartner MO. 2000. The biochemistry of apoptosis. Nature 407:770-76
26. Wang X. 2001. The expanding role of mitochondria in apoptosis. Genes Dev. 15:2922-33
27. Mattson MP, Kroemer G. 2003. Mitochondria in cell death: novel targets for neuroprotection and cardioprotection. Trends Mol. Med. 9:196-205
28. Ishitani R, Sunaga K, Hirano A, Saunders P, Katsube N, Chuang D-M. 1996. Evidence that glyceraldehyde-3-phosphate dehydrogenase is involved in age-induced apoptosis in mature cerebellar granule neurons in culture. J. Neurochem. 66:928-35
29. Ishitani R, Kimura M, Sunaga K, Katsube N, Tanaka M, Chuang D-M. 1996. An antisense oligodeoxynucleotide to glyceraldehyde-3-phosphate dehydrogenase blocks age-induced apoptosis of mature cerebrocortical neurons in culture. J. Pharmacol. Exp. Ther. 278:447-54
30. +-induced apoptosis, but not necrosis, of cultured cerebellar granule cells. Mol. Pharmacol. 51:542-50
31. Chen R-W, Saunders PA, Wei H, Li Z, Seth P, Chuang D-M. 1999. Involvement of GAPDH and p53 in neuronal apoptosis: evidence that GAPDH is upregulated by p53. J. Neurosci. 19:9654-62
32. Ishitani R, Chuang D-M. 1996. Glyceraldehyde-3-phosphate dehydrogenase antisense oligodeoxynucleotides protect against cytosine arabinoside-induced apoptosis in cultured cerebellar neurons. Proc. Natl. Acad. Sci. USA 93:9937-41
33. Saunders PA, Chalecka-Franaszek E, Chuang D-M. 1997. Subcellular distribution of GAPDH in cerebellar granule cells undergoing cytosine arabinoside-induced apoptosis. J. Neurochem. 69:1820-28
34. Sawa A, Khan AA, Hester LD, Snyder SH. 1997. Glyceraldehyde-3-phosphate dehydrogenase: nuclear translocation participates in neuronal and nonneuronal cell death. Proc. Natl. Acad. Sci. USA 94:11669-74
35. Ishitani R, Tanaka M, Sunaga K, Katsube N, Chuang D-M. 1998. Nuclear localization of over-expressed glyceraldehyde-3-phosphate dehydrogenase in cultured cerebellar neurons undergoing apoptosis. Mol. Pharmacol. 53:701-7
36. Shashidharan P, Chalmers-Redman RME, Carlile GW, Rodic V, Gurvich N, et al. 1999. Nuclear translocation of GAPDH-GFP fusion protein during apoptosis. NeuroReport 10:1149-53
37. Saunders PA, Chen R-W, Chuang D-M. 1999. Nuclear translocation of glyceraldehyde-3-phosphate dehydrogenase isoforms during neuronal apoptosis. J. Neurochem. 72:925-32
38. Epner DE, Sawa A, Isaacs JT. 1999. Glyceraldehyde-3-phosphate dehydrogenase expression during apoptosis and proliferation of rat ventral prostate. Biol. Reprod. 61:687-91
39. +-induced apoptosis. NeuroReport 12:2049-52
40. +)-induced apoptosis in SK-N-SH neurons. J. Neurocytol. 32:329-43
41. Maruyama W, Akao Y, Youdim MBH, Davis BA, Naoi M. 2001. Transfection-enforced Bcl-2 over-expression and an anti-Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, N-methyl-(R)-salsolinol. J. Neurochem. 78:727-35
42. Dastoor Z, Dreyer JL. 2001. Potential role of nuclear translocation of glyceraldehyde-3-phosphate dehydrogenase in apoptosis and oxidative stress. J. Cell Sci. 114:1643-53
43. Hara M, Agarawal N, Luo X, Fujii K, Snyder SH, Sawa A. 2001. Oxidative modification of GAPDH and neuronal cell death; a trigger to initiate a death cascade via Siah and N-coR. Annu. Meet. Soc. Neurosci. Abstr. No. 19.11
44. Kragten E, Lalande I, Zimmermann K, Roggo S, Schindler P, et al. 1998. Glyceraldehyde-3-phosphate dehydrogenase, the putative target of the antiapoptotic compounds CGP 3466 and R-(-)-deprenyl. J. Biol. Chem. 273:5821-28
45. Tajima H, Tsuchiya K, Yamada M, Kondo K, Katsube N, Ishitani R. 1999. Over-expression of GAPDH induces apoptosis in COS-7 cells transfected with cloned GAPDH cDNAs. NeuroReport 10:2029-33
46. Chen R-W, Wei H, Leng Y, Wei W, Saunders PA, et al. 1999. Bcl-2 suppresses nuclear levels of glyceraldehyde-3-phosphate dehydrogenase and protects against apoptosis induced by thapsigargin and buthionine sulfoximine. Annu. Meet. Soc. Neurosci. Abstr. No. 606.19
47. Maruyama W, Oya-Ito T, Shamoto-Nagai M, Osawa T, Naoi M. 2002. Glyceraldehyde-3-phosphate dehydrogenase is translocated into nuclei through Golgi apparatus during apoptosis induced by 6-hydroxydopamine in human dopaminergic SH-SY5Y cells. Neurosci. Lett. 321:29-32
48. Sawa A, Agrawal N, Hara M, Luo X, Snyder SH. 2001. Roles of N-CoR (nuclear receptor corepressor) degradation in neuronal cell death: a main target of apoptotic cascade by GAPDH/Siah. Annu. Meet. Soc. Neurosci. Abstr. No. 19.10
49. Roperch JP, Lethrone F, Prieur S, Piouffre L, Israeli D, et al. 1999. SIAH-1 promotes apoptosis and tumor suppression through a network involving the regulation of protein folding, unfolding, and trafficking: identification of common effectors with p53 and p21(Waf1). Proc. Natl. Acad. Sci. USA 96:8070-73
50. Fiucci G, Beaucourt S, Duflaut D, Lespagnol A, Stumptner-Cuvelette P, et al. 2004. Siah-1b is a direct transcriptional target of p53: Identification of the functional p53 responsive element in the siah-1b promoter. Proc. Natl. Acad. Sci. USA 101:3510-15
51. Relaix F, Wei XJ, Li W, Pan JJ, Lin YH, et al. 2000. Pw1/Peg3 is a potential cell death mediator and cooperates with Siah1a in p53-mediated apoptosis. Proc. Natl. Acad. Sci. USA 97:2105-10
52. Susini L, Passer BJ, Amzallag-Elbaz N, Juven-Gershon T, Prieur S, et al. 2001. Siah-1 binds and regulates the function of Numb. Proc. Natl. Acad. Sci. USA 98:15067-72
53. Rogalski AA, Steck TL, Waseem A. 1989. Association of glyceraldehyde-3-phosphate dehydrogenase with the plasma-membrane of the intact human red blood-cell. J. Biol. Chem. 264:6438-46
54. Schmitz HD. 2001. Reversible nuclear translocation of glyceraldehyde-3-phosphate dehydrogenase upon serum depletion. Eur. J. Cell Biol. 80:419-27
55. Schmitz HD, Dutine C, Bereiter-Hahn J. 2003. Exportin 1-independent nuclear export of GAPDH. Cell Biol. Int. 27:511-17
56. Brown VM, Krynetski EY, Krynetskaia NF, Grieger D, Mukatira ST, et al. 2004. A novel CRM1-mediated nuclear export signal governs nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase following genotoxic stress. J. Biol. Chem. 279:5984-92
57. Nahlik KW, Mleczko AK, Gawlik MK, Rokita HB. 2003. Modulation of GAPDH expression and cellular localization after vaccinia virus infection of human adherent monocytes. Acta Biochim. Pol. 50:667-76
58. Mazzola JL, Sirover MA. 2003. Subcellular alteration of glyceraldehyde-3-phosphate dehydrogenase in Alzheimer's disease fibroblasls. J. Neurosci. Res. 71:279-85
59. Kanai H, Sawa A, Chen R-W, Leeds P, Chuang D-M. 2004. Valproic acid inhibits histone deacetylase activity and suppresses excitotoxicity-induced GAPDH nuclear accumulation and apoptotic death in neurons. Pharmagenomics J. 4:336-44
60. Zheng L, Roeder RG, Luo Y. 2003. S phase activation of the histone H2B promoter by OCA-S, a coactivator complex lhal contains GAPDH as a key component. Cell 114:255-66
61. Krynetski EY, Krynetskaia NF, Bianchi ME, Evans WE. 2003. A nuclear protein complex containing high mobility group proteins B1 and B2, heat shock cognate protein 70, ERp60, and glyceraldehyde-3-phosphate dehydrogenase is involved in the cytotoxic response to DNA modified by incorporation of anticancer nucleoside analogues. Cancer Res. 63:100-6
62. Mohr S, Hallak H, de Boitte A, Lapetina EG, Brune B. 1999. Nitric oxide-induced S-glutathionylation and inactivation of glyceraldehyde-3-phosphate dehydrogenase. J. Biol. Chem. 274:9427-30
63. 2+ ions with glyceraldehyde-3-phosphate dehydrogenase from bovine heart and rabbit muscle. Int. J. Biochem. 24:1501-5
64. Mohr S, Stomler JS, Brune B. 1996. Post-translational modification of glyceraldehyde-3-phosphate dehydrogenase by S-nitrosylation and subsequent NADH attachment. J. Biol. Chem. 271:4209-14
65. Pancholi V, Fischetti VA. 1993. Glyceraldehyde-3-phosphate dehydrogenase on the surface of group A streptococci is also an ADP-ribosylating enzyme. Proc. Natl. Acad. Sci. USA 90:8154-58
66. Zolkiewska A, Nightingale MS, Moss J. 1992. Molecular characterization of NAD:arginine ADP-ribosyltransferase from rabbit skeletal muscle. Proc. Natl. Acad. Sci. USA 89:11352-56
67. Cahuana GM, Tejedo JR, Jimenez J, Ramirez R, Sobrino F, Bedoya FJ. 2004. Nitric oxide-induced carbonylation of Bcl-2, GAPDH and ANT precedes apoptotic events in insulin-secreting RINm5F cells. Exp. Cell. Res. 293:22-30
68. Brune B, Mohr S. 2001. Protein thiol modification of glyceraldehyde-3- phosphate dehydrogenase and caspase-3 by nitric oxide. Curr. Protein Pept. Sci. 2:61-72
69. Yasuda M, Fujimori H, Panhou H. 1998. NO depletes cellular ATP contents via inactivation of glyceraldehyde-3-phosphate dehydrogenase in PC12 cells. J. Toxicol. Sci. 23:389-94
70. Albina JE, Mastrofrancesco B, Reichner JS. 1999. Acyl phosphatase activity of NO-inhibited glyceraldehyde-3-phosphate dehydrogenase (GAPDH): a potential mechanism for uncoupling glycolysis from ATP generation in NO-producing cells. Biochem. J. 341:5-9
71. Arutyunov DY, Muronetz VI. 2003. The activation of glycolysis performed by the non-phosphorylating glyceraldehyde-3-phosphate dehydrogenase in the model system. Biochem. Biophys. Res. Commun. 300:149-54
72. Buchczyk DP, Briviba K, Harti FU, Sies H. 2000. Responses to peroxynitrite in yeast: glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as a sensitive intracellular target for nitration and enhancement of chaperone expression and ubiquitination. Biol. Chem. 381:121-26
73. Buchczyk DP, Grune T, Sies H, Klotz LO. 2003. Modifications of glyceraldehyde-3-phosphate dehydrogenase induced by increasing concentrations of peroxynitrite: early recognition by 20S proteasome. Biol. Chem. 384:237-41
74. Blumenfeld N, Gonen H, Mayer A, Smith CE, Siegel NR, et al. 1994. Purification and characterization of a novel species of ubiquitin-carrier protein, E2, that is involved in degradation of non-"N-end rule" protein substrates. J. Biol. Chem. 269:9574-81
75. Bercovich B, Stancovski I, Mayer A, Blumenfeld N, Laszlo A, et al. 1997. Ubiquitin-dependent degradation of certain protein substrates in vitro requires the molecular chaperone Hsc70. J. Biol. Chem. 272:9002-10
76. Arutyunova EI, Danshina PV, Domnina LV, Pleten AP, Muronetz VI. 2003. Oxidation of glyceraldehyde-3-phosphate dehydrogenase enhances its binding to nucleic acids. Biochem. Biophys. Res. Commun. 307:547-52
77. Moras D, Olsen KW, Sabesan MN, Buehner M, Ford GC, Rossmann MG. 1975. Studies of asymmetry in the three-dimensional structure of lobster D-glyceraldehyde-3-phosphate dehydrogenase. J. Biol. Chem. 250:9137-62
78. Yi M, Schultz DE, Lemon SM. 2000. Functional significance of the interaction of hepatitis A virus RNA with glyceraldehyde 3-phosphate dehydrogenase (GAPDH): opposing effects of GAPDH and polypyrimidine tract binding protein on internal ribosome entry site function. J. Virol. 74:6459-68
79. Engel M, Seifert M, Theisinger B, Seyfert U, Welter C. 1998. Glyceraldehyde-3-phosphate dehydrogenase and Nm23-H1/nucleoside diphosphate kinase A. Two old enzymes combine for the novel Nm23 protein phosphotransferase function. J. Biol. Chem. 273:20058-65
80. Ito Y, Pagano PJ, Tomheim K, Brecher P, Cohen RA. 1996. Oxidative stress increases glyceraldehyde-3-phosphate dehydrogenase mRNA levels in isolated rabbit aorta. Am. J. Physiol. Heart Circ. Physiol. 270:H81-87
81. Hainaut P, Mann K. 2001. Zinc binding and redox control of p53 structure and function. Antioxid. Redox. Signal 3:611-23
82. Vogelstein B, Lane D, Levine AJ. 2000. Surfing the p53 network. Nature 408:307-10
83. Trinei M, Giorgio M, Cicalese A, Barozzi S, Ventura A, et al. 2002. A p53-p66Shc signalling pathway controls intracellular redox status, levels of oxidation-damaged DNA and oxidative stress-induced apoptosis. Oncogene 21:3872-78
84. Orsini F, Migliaccio E, Moroni M, Contursi C, Raker VA, et al. 2004. The life span determinant p66Shc localizes to mitochondria where it associates with mtHsp70 and regulates trans-membrane potential. J. Biol. Chem. 279:25689-95
85. Luo J, Li M, Tang Y, Laszkowska M, Roeder RG, Gu W. 2004. Acetylation of p53 augments its site-specific DNA binding both in vitro and in vivo. Proc. Natl. Acad. Sci. USA 101:2259-64
86. Smith JS. 2002. Human Sir2 and the 'silencing' of p53 activity. Trends Cell Biol. 12:404-6
87. Friedlander RM. 2003. Apoptosis and caspases in neurodegenerative diseases. New Engl. J. Med. 348:1365-75
88. Sharp FR, Lu AG, Tang Y, Millhorn DE. 2000. Multiple molecular penumbras after focal cerebral ischemia. J. Cerebr. Blood Flow Met. 20:1011-32
89. Love S. 2003. Apoptosis and brain ischaemia. Prog. NeuroPsychopharmacol. Biol. Psychiatry 27:267-82
90. Burke JR, Enghild JJ, Martin ME, Jou YS, Myers RM, et al. 1996. Huntington and DRPLA proteins selectively interact with the enzyme GAPDH. Nat. Med. 2:347-50
91. Koshy B, Matilla T, Burright EN, Merry DE, Fischbeck KH, et al. 1996. Spinocerebellar ataxia type-1 and spinobulbar muscular atrophy gene products interact with glyceraldehyde-3-phosphate dehydrogenase. Hum. Mol. Genet. 5:1311-18
92. Shiozawa M, Fukutani Y, Arai N, Cairns NJ, Mizutani T, et al. 2003. Glyceraldehyde 3-phosphate dehydrogenase and endothelin-1 immunoreactivity is associated with cerebral white matter damage in dentatorubral-pallidoluysian atrophy. Neuropathology 23:36-43
93. Browne SE, Bowling AC, MacGarvey U, Baik MJ, Berger SC, et al. 1997. Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Ann. Neurol. 41:646-53
94. Kish SJ, Lopes-Cendes I, Guttman M, Furukawa Y, Pandolfo M, et al. 1998. Brain glyceraldehyde-3-phosphate dehydrogenase activity in human trinucleotide repeat disorders. Arch. Neurol. 55:1299-304
95. Cooper AJL, Sheu KFR, Burke JR, Strittmatter WJ, Blass JP. 1998. Glyceraldehyde 3-phosphate dehydrogenase abnormality in metabolically stressed Huntington disease fibroblasts. Dev. Neurosci. 20:462-68
96. Mazzola JL, Sirover MA. 2001. Reduction of glyceraldehyde-3-phosphate dehydrogenase activity in Alzheimer's disease and in Huntington's disease fibroblasts. J. Neurochem. 76:442-49
97. Mazzola JL, Sirover MA. 2002. Alteration of nuclear glyceraldehyde-3- phosphate dehydrogenase structure in Huntington's disease fibroblasts. Mol. Brain Res. 100:95-101
98. Cooper AJL, Sheu KFR, Burke JR, Onodera O, Stritmatter WJ, et al. 1997. Transglutaminase-catalyzed inactivation of glyceraldehyde 3-phosphate dehydrogenase and alpha-ketoglutarate dehydrogenase complex by polyglutamine domains of pathological length. Proc. Natl. Acad. Sci. USA 94:12604-9
99. Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, et al. 1996. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87:493-506
100. Reddy PH, Williams M, Charles V, Garrett L, Pike-Buchanan L, et al. 1998. Behavioural abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length HD cDNA. Nat. Genet. 20:198-202
101. Hodgson JG, Agopyan N, Gutekunst CA, Leavitt BR, LePiane F, et al. 1999. A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron 23:181-92
102. Schilling G, Becher MW, Sharp AH, Jinnah HA, Duan K, et al. 1999. Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum. Mol. Genet. 8:397-407
103. Laforet GA, Sapp E, Chase K, McIntyre C, Boyce FM, et al. 2001. Changes in cortical and striatal neurons predict behavioral and electrophysiological abnormalities in a transgenic murine model of Huntington's disease. J. Neurosci. 21:9112-23
104. Slow EJ, van Raamsdonk J, Rogers D, Coleman SH, Graham RK, et al. 2003. Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum. Mol. Genet. 12:1555-67
105. Senatorov W, Charles V, Reddy PH, Tagle DA, Chuang D-M. 2003. Overexpression and nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase in a transgenic mouse model of Huntington's disease. Mol. Cell. Neurosci. 22:285-97
106. Selkoe DJ. 2001. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 81:741-66
107. Schulze H, Schuler A, Stüber D, Döbeli H, Langer H, Huber G. 1993. Rat-brain glyceraldehyde-3-phosphate dehydrogenase interacts with the recombinant cytoplasmic domain of Alzheimers beta-amyloid precursor protein. J. Neurochem. 60:1915-22
108. Cupers P, Orlans I, Craessaerts K, Annaert W, De Strooper B. 2001. The amyloid precursor protein (APP)-cytoplasmic fragment generated by gamma-secretase is rapidly degraded but distributes partially in a nuclear fraction of neurones in culture. J. Neurochem. 78:1168-78
109. Kimberly WT, Zheng JB, Guenette SY, Selkoe DJ. 2001. The intracellular domain of the beta-amyloid precursor protein is stabilized by Fe65 and translocates to the nucleus in a Notch-like manner. J. Biol. Chem. 276:40288-92
110. Sunaga K, Takahashi H, Chuang D-M, Ishitani, R. 1995. Glyceraldehyde-3-phosphate dehydrogenase is over-expressed during apoptotic death of neuronal cultures and is recognized by a monoclonal antibody against amyloid plaques from Alzheimer's brain. Neurosci. Lett. 200:133-36
111. Tamaoka A, Endoh R, Shoji S, Takahashi H, Hirokawa K, et al. 1996. Antibodies to amyloid beta protein (A beta) crossreact with glyceraldehyde-3- phosphate dehydrogenase (GAPDH). Neurobiol. Aging 17:405-14
112. Kuwae T, Yamada M, Takahashi H, Tsuchiya K, Tajima H, et al. 2002. Pro-apoptotic protein GAPDH: a possible site of action of anti-dementia drugs. Annu. Meet. Soc. Neurosci. Abstr. No. 884.4
113. Lubec G, Labudova O, Cairns N, Fountoulakis M. 1999. Increased glyceraldehyde 3-phosphate dehydrogenase levels in the brain of patients with Down's syndrome. Neurosci. Lett. 260:141-45
114. Tsuchiya K, Tajima H, Yamada M, Takahashi H, Kuwae T, et al. 2004. Disclosure of a pro-apoptotic glyceraldehyde-3-phosphate dehydrogenase promoter; antidementia drugs depress its activation in apoptosis. Life Sci. 74:3245-58
115. Katsube N, Sunaga K, Chuang D-M, Ishitani R. 1996. ONO-1603, a potential antidementia drug, shows neuroprotective effects and increases m3-muscarinic receptor mRNA levels in differentiating cerebellar granule cells. Neurosci. Lett. 214:151-54
116. Katsube N, Sunaga K, Aishita H, Chuang D-M, Ishitani R. 1999. ONO-163, a potential antidementia drug, protects against age-induced apoptosis and suppresses over-expression of GAPDH in cultured CNS neurons. J. Pharmacol. Exp. Ther. 288:6-13
117. Carlile GW, Chalmers-Redman RME, Tatton NA, Pong A, Borden KE, Tatton WG. 2000. Reduced apoptosis after nerve growth factor and serum withdrawal: conversion of tetrameric glyceraldehyde-3-phosphate dehydrogenase to a dimmer. Mol. Pharmacol. 57:2-12
118. Berry MD. 1999. An orally active agent combining independent anti-apoptotic and MAO-B-inhibiting activities. CNS Drug Rev. 5:105-24
119. Tatton NA. 2000. Increased caspase 3 and Bax immunoreactivity accompany nuclear GAPDH translocation and neuronal apoptosis in Parkinson's disease. Exp. Neurol. 166:29-43
120. Lipton P. 1999. Ischemic cell death in brain neurons. Physiol. Rev. 79:1431-68
121. Tanaka R, Mochizuki H, Suzuki A, Katsube N, Ishitani R, et al. 2002. Induction of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression in rat brain after focal ischemia/reperfusion. J. Cereb. Blood Flow Metab. 22:280-88
122. Graven KK, Troxler RF, Kornfeld H, Panchenko MV, Farber HW. 1994. Regulation of endothelial-cell glyceraldehyde-3-phosphate dehydrogenase expression by hypoxia. J. Biol. Chem. 269:24446-53
123. Graven KK, Yu Q, Pan D, Roncarati JS, Farber HW. 1999. Identification of an oxygen responsive enhancer element in the glyceraldehyde-3-phosphate dehydrogenase gene. Biochim. Biophys. Acta Gene Struct. Expres. 1447:208-18
124. Lu S, Gu X, Hoestje S, Epner DE. 2002. Identification of an additional hypoxia responsive element in the glyceraldehyde-3-phosphate dehydrogenase gene promoter. Biochim. Biophys. Acta Gene Struct. Expres. 1574:152-56
125. 2+ exchanger. Biochim. Biophys. Acta Mol. Cell Res. 1593:269-76
126. Nakamura T, Hinagata J, Tanaka T, Imanishi T, Wada Y, et al. 2002. HSP90, HSP70, and GAPDH directly interact with the cytoplasmic domain of macrophage scavenger receptors. Biochem. Biophys. Res. Comm. 290:858-64
127. Ren M, Senatorov VV, Chen RW, Chuang D-M. 2003. Postinsult treatment with lithium reduces brain damage and facilitates neurological recovery in a rat ischemia/reperfusion model. Proc. Natl. Acad. Sci. USA 100:6210-15
128. Ren M, Leng Y, Jeong MR, Leeds PR, Chuang D-M. 2004. Valproic acid reduces brain damage induced by transient focal cerebral ischemia in rats: potential roles of histone deacetylase inhibition and heat shock protein induction. J. Neurochem. 89:1358-67